Key Performance
More- Earnings Score: 49
- Momentum Score: 23
- True Yield: N/A
- Financial Health Score: 30
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
FDA Flags High-Risk Recall For Tandem Diabetes Mobi Pumps
The FDA has classified a Class I recall for Tandem Diabetes Care's Mobi insulin pumps due to a potential 'false motor failure' detection that could halt insulin delivery. Affected devices running software versions 7.6.0.1, 7.6.0.3, and 7.7.0.1 must be updated to version 7.9.0.2. As of November 4, 2025, four serious injuries have been reported with no deaths. Users are advised to have backup insulin delivery methods ready.
04/24/2026, 2:18 PM • Benzinga
Tandem Diabetes Care, Inc. Investigated by the Portnoy Law Firm
The Portnoy Law Firm has initiated a securities fraud investigation into Tandem Diabetes Care following a 19.9% stock price decline on August 7, 2025. The drop was triggered by the company's disclosure of a malfunction in its insulin pumps that could discontinue insulin delivery and cause hyperglycemia. Tandem had notified affected customers before the public market disclosure.
03/27/2026, 9:00 AM • GlobeNewswire
The global intravenous infusion pump market was valued at USD 6.72 billion in 2025 and is projected to reach USD 14.02 billion by 2035, growing at a CAGR of 7.6%. Growth is driven by increasing chronic diseases, aging populations, technological advancements in smart pumps, and rising demand for precise medication delivery in hospitals and home care settings.
03/09/2026, 6:30 PM • GlobeNewswire
Tandem Diabetes Shares Rise 33% On Earnings Beat, Margin Expansion, Growth Outlook
Tandem Diabetes Care (NASDAQ: TNDM) shares surged 33-37% following strong Q4 earnings results that beat expectations with adjusted loss of $0.01 vs. consensus loss of $0.08, and sales of $290.4M exceeding the $277M consensus. The company reported significant margin expansion with adjusted gross profit jumping from 51% to 58%, and adjusted operating profit of $8.3M versus a $30.2M loss year-ago. For 2026, the company forecasts sales of $1.065-$1.085B and expects 5-6% adjusted EBITDA margins, though slightly below consensus expectations. Management highlighted plans for double-digit pump shipment growth and a new pay-as-you-go model to improve profitability.
02/20/2026, 1:01 PM • Benzinga
The Rosen Law Firm is investigating potential securities claims on behalf of Tandem Diabetes Care shareholders following the company's August 7, 2025 announcement of a voluntary medical device correction for select t:slim X2 insulin pumps due to a speaker-related issue that could discontinue insulin delivery. The stock fell 19.9% on the news. The firm is preparing a class action lawsuit to recover investor losses.
02/08/2026, 12:23 PM • GlobeNewswire
The Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care (TNDM) following the company's August 7, 2025 announcement of a voluntary medical device correction for select t:slim X2 insulin pumps due to a speaker-related issue that could discontinue insulin delivery. The stock fell 19.9% on the news. The firm is preparing a class action lawsuit to recover investor losses.
02/05/2026, 8:24 PM • GlobeNewswire
The Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. following the company's August 7, 2025 announcement of a voluntary medical device correction for select t:slim X2 insulin pumps due to a speaker-related issue that could discontinue insulin delivery. The stock fell 19.9% on the announcement. Investors who purchased TNDM securities may be eligible for compensation through a class action lawsuit.
01/30/2026, 6:07 PM • GlobeNewswire
Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) following allegations that the company disclosed materially misleading business information. On August 7, 2025, Tandem announced a voluntary recall of its t:slim X2 insulin pumps due to a potential speaker issue that could cause insulin delivery to stop. The stock declined 19.9% following the announcement. Investors who purchased Tandem securities may be eligible for compensation.
01/18/2026, 4:33 AM • GlobeNewswire
The Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. following the company's August 7, 2025 announcement of a voluntary medical device correction for select t:slim X2 insulin pumps due to a speaker-related issue that could discontinue insulin delivery. The stock fell 19.9% on the announcement date. The firm is preparing a class action lawsuit to recover investor losses.
01/17/2026, 10:40 PM • GlobeNewswire
Rosen Law Firm is encouraging investors in Skye Bioscience, SLM Corporation (Sallie Mae), and Tandem Diabetes Care to join securities class action lawsuits. The firm alleges that Skye Bioscience made materially false statements regarding the effectiveness and prospects of its drug nimacimab. Investors who purchased securities during specified class periods may be eligible for compensation, with a January 16, 2026 deadline to serve as lead plaintiff.
12/26/2025, 5:23 PM • GlobeNewswire
The Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. following the company's August 7, 2025 announcement of a voluntary medical device correction for select t:slim X2 insulin pumps due to a speaker-related issue that could discontinue insulin delivery. The stock fell 19.9% on the announcement. The firm is preparing a class action lawsuit to recover investor losses.
12/26/2025, 3:20 PM • GlobeNewswire
The Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care (TNDM) following the company's August 7, 2025 announcement of a voluntary medical device correction for select t:slim X2 insulin pumps due to a speaker-related issue that could discontinue insulin delivery. The stock fell 19.9% on the announcement date. The firm is preparing a class action lawsuit to recover investor losses.
12/19/2025, 8:07 PM • GlobeNewswire
Rosen Law Firm is investigating potential securities claims for Tandem Diabetes Care shareholders following a voluntary medical device correction that caused the stock to drop 19.9% on August 7, 2025.
12/13/2025, 1:19 PM • GlobeNewswire
Rosen Law Firm is investigating potential securities claims for Tandem Diabetes Care shareholders following a voluntary medical device correction that caused a significant stock price drop.
12/10/2025, 3:51 PM • GlobeNewswire
Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care due to a voluntary medical device correction for t:slim X2 insulin pumps that caused a 19.9% stock price drop.
11/27/2025, 12:45 PM • GlobeNewswire
